Huntington's Disease Society of America (HDSA) Center of Excellence at the Neurological Institute of New York
Columbia University's HDSA Center of Excellence offers comprehensive services for individuals affected by Huntington's Disease (HD) and their families. We provide direct patient care as well as opportunities to participate in research to better understand and treat HD.
Our specialized multidisciplinary team of health professionals provides the highest level of clinical care for HD patients and their families. In addition to neurological, and psychiatric diagnosis and treatment, we offer social services, and a genetic counseling and testing program. Physical and occupational therapy are offered on-site at the Neurological Institute at 710 W168th street. The Center operates on Fridays from 8:00 AM to 1:00 PM, by appointment only. We actively participate in the Huntington Study Group (HSG), a national consortium of HD Centers. We are currently recruiting for the following studies:
Research
Clinical Trials
Huntington’s disease: DIMENSION (SAGE-718-201). NCT05107128
Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease. Duration: 112 days. Participants must have a total functional capacity score (TFC) ranging from 7-12 (<6 and 13 excluded) and a MoCA score <26 at the time of enrollment. Assessments will include cognitive tests, physical examinations, psychiatric assessments, Virtual Reality Functional Capacity Assessment Tool (VRFCAT), and blood tests.
PI: Dr. O’Shea; Call Jasim Uddin 212-305-4597
Huntington’s disease: SURVEYOR (SAGE-718-202). NCT05358821
Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease. Duration: 84 days. Participants must have a total functional capacity score (TFC) ranging from 7-12 (<6 and 13 excluded) and a MoCA score <26 at the time of enrollment. Assessments will include cognitive tests, physical examinations, psychiatric assessments, Virtual Reality Functional Capacity Assessment Tool (VRFCAT), and blood tests.
PI: Dr. O’Shea; Call Jasim Uddin 212-305-4597
Huntington’s disease: PURVIEW (SAGE-718-301). NCT05655520
A Phase 3, multicenter, open-label safety study to evaluate the long-term safety and tolerability of SAGE-718 in participants with Huntington’s disease. We are recruiting individuals with HD who participated in SAGE 201 as well as new participants. Duration of the study will be one year.
PI: Dr. O’Shea; Call Jasim Uddin 212-305-4597
Huntington’s Disease: Dance for HD (HDSA)
Movement Intervention for Neurodegenerative Disease (MIND): Dance for HD Phase 2. Feasibility and preliminary efficacy study. Inclusion: Diagnosed with HD. Age >18. TFC score= 7-13. Intervention= Laban-Bartenieff dance technique, 2 days a week for 18 weeks. Duration: about 24 weeks. Visits: 4 (pre-assessment, baseline, post-assessment, retention). Procedures include: Neurological assessment, balance and gait test, cognitive test, quality of life questionnaire.
PI: Dr. Rao Call Corey Landis 212-305-1647
Accordion Title (required)
Accordion content...
Observational study
ENROLL HD: NCT01574053 (CHDI)
Enroll-HD is a longitudinal, observational, multinational study whose goal is to develop a comprehensive repository of prospective and systematically collected clinical research data (demography, clinical features, family history, genetic characteristics) and biological specimens (blood) from individuals with manifest HD, unaffected individuals known to carry the HD mutation or at risk of carrying the HD mutation, and control research participants (e.g., spouses, siblings or offspring of HD mutation carriers known not to carry the HD mutation). More than 20,000 participants have now enrolled into the study for annual assessments (www.enroll-hd.org/for-researchers/access-data/) to learn more.
PI Karen Marder. Call Jasim Uddin 212 305 -4597
Huntington’s Disease: CHANGE-HD NCT01860339
Child to Adult Neurodevelopment in Gene Expanded Huntington’s Disease
Duration: 5 years, yearly visit Inclusion: Ages 6-30 with parent/grandparent with HD, Procedures: blood draw, structural MRI, lifestyle questionnaires, cognitive tests, motor tests.
PI:Dr. Rao Call Jennifer Oscherician 212-305-1647
For more information about participating in research, please contact Jasim Uddin at (212) 305-4597 or via email at ju2189@cumc.columbia.edu.
For more clinical trials and studies, please visit the Taub Institute for Research on Alzheimer's Disease and the Aging Brain website.
HD Clinic
For new referrals and appointments at the Neurological Institute, please contact Deborah Thorne, LCSW at (212) 305-9172 or via email at dzt1@cumc.columbia.edu.
Genetic counseling and testing, please contact Amanda Bergner, CGC at 212 304 7703 or at ab4607@cumc.columbia.edu.
Staff
Karen Marder MD MPH – Attending Neurologist, COE Director
Deborah Thorne, LCSW – Social Worker, Director of Clinical Care
Sarah A. O'Shea, MD – Attending Neurologist
Amanda Bergner MS, CGC – Genetic counselor
Ashwini Rao, EdD, OTR – Occupational Therapy
Lori Quinn, EdD, PT – Physical Therapy
Jill Goldman, MS, MPhil, CGC – Genetic Counselor
Jasim Uddin – Clinical and Research Coordinator
Miles DeGrazia – Research Assistant
Vanessa Torres– Research Assistant
Rumsha Javed – Research Assistant
Other Helpful Resources
Huntington's Disease Society of America (HDSA)
Principal Investigator
Karen S. Marder, MD, MPH
- Sally Kerlin Professor of Neurology (in the Gertrude H. Sergievsky Center, in the Taub Institute on Alzheimer's Disease and the Aging Brain, and in Psychiatry) at CUMC
